Figure 4. BMSC-CM activated fibroblasts by activating the JAK2/STAT4 pathway. (A) The expression of JAK2, p-JAK2, STAT4, and p-STAT4 in fibroblasts treated with different media was determined by western blotting. (B) The expression of three most significant DEGs (POSTN, COMP, and TGFBI) in fibroblasts treated with JAK2 inhibitor AG490 (10 μM). (C) Wound–scratch assay in fibroblasts treated with or without JAK2 inhibitor AG490 (10 μM) at 0 h, 24 h, and 48 h (magnification, ×40). Scale bar = 400 μm. (D) The percentage of migration area in different groups. (E) The CCK-8 assay showing reduced proliferation of fibroblasts treated with BMSC-CM after treatment with AG490. (F) Collagen synthesis in fibroblasts after AG490 treatment was determined by RT-PCR. Data are shown as means ± standard deviation (SD). *P < 0.05; **P < 0.01; ***P < 0.001. BMSC-CM, bone marrow stem cell-conditioned medium; con, control medium treatment group; CM, BMSC-CM treatment group.